KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Finished Goods: 2011-2013

Historic Finished Goods for Pacira BioSciences (PCRX) over the last 1 years, with Jun 2013 value amounting to $4.3 million.

  • Pacira BioSciences' Finished Goods fell 5.81% to $4.3 million in Q2 2013 from the same period last year, while for Jun 2013 it was $4.3 million, marking a year-over-year decrease of 5.81%. This contributed to the annual value of $2.0 million for FY2012, which is 602.79% up from last year.
  • As of Q2 2013, Pacira BioSciences' Finished Goods stood at $4.3 million, which was up 12.65% from $3.8 million recorded in Q1 2013.
  • In the past 5 years, Pacira BioSciences' Finished Goods ranged from a high of $6.4 million in Q3 2012 and a low of $287,000 during Q4 2011.
  • For the 3-year period, Pacira BioSciences' Finished Goods averaged around $3.5 million, with its median value being $4.0 million (2013).
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 602.79% in 2012, then declined by 5.81% in 2013.
  • Quarterly analysis of 3 years shows Pacira BioSciences' Finished Goods stood at $287,000 in 2011, then surged by 602.79% to $2.0 million in 2012, then declined by 5.81% to $4.3 million in 2013.
  • Its Finished Goods was $4.3 million in Q2 2013, compared to $3.8 million in Q1 2013 and $2.0 million in Q4 2012.